Status:

RECRUITING

BIO|CONCEPT.BIOMONITOR-HF Collect Clinical Data From Heart Failure Patients Using BIOMONITOR Devices With a Study Specific Research Software

Lead Sponsor:

Biotronik SE & Co. KG

Conditions:

Heart Failure

Arrhythmia

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

\[Plain language\]: Heart failure (HF) patients often experience irregular heartbeats, known as arrhythmias. Atrial fibrillation (AF) is common among HF patients and can worsen their condition, leadin...

Detailed Description

This study aims to collect clinical data with regard to the two main study objectives: \- Objective arrhythmia: Assess the incidence of arrhythmias and the contribution of the BIOMONITOR to arrhythmi...

Eligibility Criteria

Inclusion

  • Patient has diagnosed heart failure for ≥90 days and current symptoms compatible with NYHA class II-III (according to most recent assessment)
  • At least ONE of the following:
  • At least one documented admission with a primary diagnosis of worsening heart failure within last 12 months prior to enrollment;
  • OR Unscheduled outpatient visit with increase of oral loop diuretics (more than 2-fold) or IV diuretic or ultrafiltration therapy for acute WHF within last 6 months prior to enrollment;
  • OR elevated NT-proBNP/BNP values within last 3 months prior to enrollment i.e.:
  • If LVEF \>50% --\> Patients in SR: \>450 / \>150 pg/ml; Patients with AF present: \>900 / \>300 pg/ml
  • If LVEF \<50% --\> Patients in SR: \>900 / \>300 pg/ml; Patients with AF present: \>1800 / \>450 pg/ml
  • Ability to understand the nature of the study
  • Willingness to provide written informed consent
  • Ability and willingness to perform follow-up visits at the study site and via phone
  • Ability and willingness to use the CardioMessenger and acceptance of the BIOTRONIK Home Monitoring concept

Exclusion

  • Implanted with pacemaker, ICD or CRT device or ICM
  • Class I indication for a pacemaker, ICD or CRT according to current guidelines.
  • Permanent or long-standing persistent AF
  • Stroke, MI or PCI/CABG within 3 months prior to enrollment
  • Patient is on chronic renal or peritoneal dialysis
  • Patient has complex adult congenital heart disease
  • Patient has active cancer involving chemotherapy, immunotherapy or radiation therapy
  • Patient life expectancy is less than 1 year
  • Age \<18 years
  • Patient is participating in any other device or drug trial that may interfere with the treatment or protocol of this study or may significantly affect the study outcomes

Key Trial Info

Start Date :

August 22 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2028

Estimated Enrollment :

300 Patients enrolled

Trial Details

Trial ID

NCT06989580

Start Date

August 22 2025

End Date

December 31 2028

Last Update

September 8 2025

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Ziekenhuis Oost Limburg AV

Genk, Belgium

2

Peter Osypka Herzzentrum

Munich, Germany